Amylyx Pharmaceuticals, Inc. (AMLX) Tops Q1 EPS by 29c

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q1 EPS of $0.02, $0.29 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $71.43 million versus the consensus estimate of $58.32 million.

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM
• Accenture downgraded by TD Cowen on AI concerns